Compare Agilysys Inc (AGYS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilysys Inc vs Merck & Co., Inc. — how do they compare? Agilysys Inc trades at $106.62 (market cap $3.18B), while Merck & Co., Inc. trades at $126.49 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 100.1× Agilysys Inc's market cap, and Merck & Co., Inc. pays a 2.64% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | MRK | |
|---|---|---|
Market Cap | $3.18B | $318.26B |
Sector | Technology | Health |
52-Week High | $141.12 | $129.52 |
52-Week Low | $62.19 | $77.60 |
Enterprise Value | $3.08B | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $111.00, up 0.17% with strong bullish technical indicators and unanimous analyst support. The stock shows robust fundamentals with 62.61% gross margins and accelerating revenue growth, projected to reach $319 million in 2026. Recent earnings beats and positive guidance highlight the company's momentum in hospitality technology solutions.
The outlook remains positive with 100% buy ratings and a $110 consensus target, though high valuation multiples (P/E 81.05) and overbought RSI levels suggest near-term consolidation risks. Long-term growth drivers include AI integration and subscription revenue expansion, but investors should monitor execution against elevated expectations.
Merck (MRK) trades at $125.84, down 0.74% on the day, with a bullish technical outlook and strong institutional support. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives amid positive analyst sentiment.
The stock offers upside to the $139.33 consensus price target, supported by solid profitability and cash flow, but faces risks from rising debt levels and competitive pressures in the pharma sector. Investors should weigh the growth potential from M&A against execution risks and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
